一项在中国健康男性受试者中进行的 PF-06439535(中国)以及欧盟来源的贝伐珠单抗给药的2 组药代动力学研究
[Translation] A 2-group pharmacokinetic study of PF-06439535 (China) and EU-derived bevacizumab administered in healthy Chinese male subjects
一项在中国健康男性受试者中进行的 PF-06439535(中国)以及欧盟来源的贝伐珠单抗给药的双盲、随机、平行组、单剂量、2 组药代动力学比对研究
[Translation] A double-blind, randomized, parallel-group, single-dose, 2-arm pharmacokinetic comparison study of PF-06439535 (China) and EU-derived bevacizumab in Chinese healthy male subjects
PF-06439535(CN)联合紫杉醇-卡铂治疗中国晚期非鳞状非小细胞肺癌参与者的随机、双盲、桥接安全性和疗效研究
[Translation] A randomized, double-blind, bridging safety and efficacy study of PF-06439535 (CN) combined with paclitaxel-carboplatin in Chinese participants with advanced non-squamous non-small cell lung cancer
基于描述性估计 PF-06439535(CN) 和贝伐珠单抗-EU的客观缓解率 (ORR) 来探索两者在疗效上的相似性,两者均与紫杉醇和卡铂联合应用。除此之外,还将评估安全性、PK 和免疫原性。
[Translation] Similarities in efficacy were explored based on descriptive estimates of objective response rate (ORR) for PF-06439535(CN) and bevacizumab-EU, both in combination with paclitaxel and carboplatin. In addition to this, safety, PK and immunogenicity will be assessed.
100 Clinical Results associated with Pfizer Biologics (Hangzhou) Co., Ltd
0 Patents (Medical) associated with Pfizer Biologics (Hangzhou) Co., Ltd
100 Deals associated with Pfizer Biologics (Hangzhou) Co., Ltd
100 Translational Medicine associated with Pfizer Biologics (Hangzhou) Co., Ltd